Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on July 11, 2025
FORTEC US and Enedo Sign Strategic U.S. Distribution Agreement
FORTEC US teams up with Enedo to Expand Power Solutions Portfolio RONKONKOMA, NY, UNITED STATES, July 11, 2025 /EINPresswire.com/ -- FORTEC US, a leading provider of industrial display, embedded, and power solutions, is pleased to announce a new …
Ola Digital Health Partners with Elite Care Provider Network to Expand Telehealth Access Across All 50 States
In a pivotal advancement for nationwide digital healthcare delivery, Ola Digital Health today announced its partnership with Elite Care Provider Network (ECPN) NEW YORK, NY, UNITED STATES, July 11, 2025 /EINPresswire.com/ -- New York, NY — [10th July …
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from cash exercise of warrants, to a …
Clarification on Leadership Announcement: Annette Slyman not to join Life Backup Plan as Chief Operating Officer
Aliso Viejo, CA, July 11, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., the developer of the Life Backup Plan app, is issuing a clarification to our July 10, 2025 press release. Annette Slyman will not be joining the team in any capacity, due to extenuating …
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable FDA clinical reviews acknowledged that the clinical data are robust and biomarker data are supportive NOVATO, Calif., July 11 …
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), …
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly …
Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health …
Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Market Trends Report
Delhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals and Future Market Opportunity Outlook 2029 Report: Report Answers Question On Why There Exist Need For Bispecific Antibody Drug …
Safest Steroid for Muscle Growth and Bodybuilding - Clinical Evidence and Safety Behind CrazyBulk's Bulking Steroids
New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) -- For decades, the use of muscle building steroids has been a driving force behind the pursuit of muscle growth and physical prowess among bodybuilders, athletes, and sports professionals. Whether …
Valneva annonce la levée de la restriction temporaire de l'Agence européenne des médicaments sur l'utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées
Saint Herblain (France), le 11 juillet 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) …
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above …
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today published a new peer-reviewed study in Neuron, a Cell Press …
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award
VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery …
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned …